nodes	percent_of_prediction	percent_of_DWPC	metapath
Phylloquinone—Scleroderma—Docetaxel—pancreatic cancer	0.0517	0.0989	CcSEcCtD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—RBBP8—pancreatic cancer	0.0485	0.102	CbGpPWpGaD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—HEY2—pancreatic cancer	0.0363	0.076	CbGpPWpGaD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—HEY1—pancreatic cancer	0.0336	0.0704	CbGpPWpGaD
Phylloquinone—GGCX—Post-translational protein modification—FUT8—pancreatic cancer	0.0191	0.04	CbGpPWpGaD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—PLAU—pancreatic cancer	0.0175	0.0366	CbGpPWpGaD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—HES1—pancreatic cancer	0.0174	0.0365	CbGpPWpGaD
Phylloquinone—Inflammation—Tamoxifen—pancreatic cancer	0.0148	0.0283	CcSEcCtD
Phylloquinone—Inflammation—Erlotinib—pancreatic cancer	0.0146	0.028	CcSEcCtD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—HIF1A—pancreatic cancer	0.0146	0.0306	CbGpPWpGaD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—KDR—pancreatic cancer	0.014	0.0292	CbGpPWpGaD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP2—pancreatic cancer	0.0138	0.0289	CbGpPWpGaD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—NOTCH1—pancreatic cancer	0.0131	0.0275	CbGpPWpGaD
Phylloquinone—BGLAP—FGF signaling pathway—PLAU—pancreatic cancer	0.0129	0.0271	CbGpPWpGaD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CDKN2A—pancreatic cancer	0.0126	0.0265	CbGpPWpGaD
Phylloquinone—Necrosis—Fluorouracil—pancreatic cancer	0.0124	0.0236	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—MET—pancreatic cancer	0.0122	0.0256	CbGpPWpGaD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—RB1—pancreatic cancer	0.0119	0.0249	CbGpPWpGaD
Phylloquinone—Swelling—Tamoxifen—pancreatic cancer	0.0118	0.0226	CcSEcCtD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CXCL8—pancreatic cancer	0.0115	0.024	CbGpPWpGaD
Phylloquinone—Hyperbilirubinaemia—Irinotecan—pancreatic cancer	0.0111	0.0213	CcSEcCtD
Phylloquinone—Hyperbilirubinaemia—Gemcitabine—pancreatic cancer	0.0108	0.0208	CcSEcCtD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CCND1—pancreatic cancer	0.0107	0.0224	CbGpPWpGaD
Phylloquinone—BGLAP—FGF signaling pathway—CDH1—pancreatic cancer	0.0106	0.0222	CbGpPWpGaD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—MET—pancreatic cancer	0.0104	0.0218	CbGpPWpGaD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP9—pancreatic cancer	0.0104	0.0217	CbGpPWpGaD
Phylloquinone—Inflammation—Fluorouracil—pancreatic cancer	0.00999	0.0191	CcSEcCtD
Phylloquinone—Injection site reaction—Gemcitabine—pancreatic cancer	0.0098	0.0188	CcSEcCtD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—PPARG—pancreatic cancer	0.00946	0.0198	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—FUT8—pancreatic cancer	0.00907	0.019	CbGpPWpGaD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—RB1—pancreatic cancer	0.00905	0.019	CbGpPWpGaD
Phylloquinone—Necrosis—Docetaxel—pancreatic cancer	0.00891	0.0171	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—SRC—pancreatic cancer	0.00832	0.0174	CbGpPWpGaD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—STAT3—pancreatic cancer	0.00803	0.0168	CbGpPWpGaD
Phylloquinone—Swelling—Fluorouracil—pancreatic cancer	0.00798	0.0153	CcSEcCtD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—CDKN2A—pancreatic cancer	0.00796	0.0167	CbGpPWpGaD
Phylloquinone—Hyperbilirubinaemia—Docetaxel—pancreatic cancer	0.00769	0.0147	CcSEcCtD
Phylloquinone—Sweating—Tamoxifen—pancreatic cancer	0.00769	0.0147	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—MMP9—pancreatic cancer	0.00766	0.016	CbGpPWpGaD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—STAT3—pancreatic cancer	0.00761	0.0159	CbGpPWpGaD
Phylloquinone—Anaphylactoid reaction—Irinotecan—pancreatic cancer	0.00759	0.0145	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—TGFB1—pancreatic cancer	0.00744	0.0156	CbGpPWpGaD
Phylloquinone—Anaphylactoid reaction—Gemcitabine—pancreatic cancer	0.00739	0.0142	CcSEcCtD
Phylloquinone—Inflammation—Docetaxel—pancreatic cancer	0.00721	0.0138	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—SRC—pancreatic cancer	0.00706	0.0148	CbGpPWpGaD
Phylloquinone—Injection site reaction—Docetaxel—pancreatic cancer	0.00696	0.0133	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—STAT3—pancreatic cancer	0.00681	0.0143	CbGpPWpGaD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—CCND1—pancreatic cancer	0.00672	0.0141	CbGpPWpGaD
Phylloquinone—Flushing—Tamoxifen—pancreatic cancer	0.00669	0.0128	CcSEcCtD
Phylloquinone—Erythema—Tamoxifen—pancreatic cancer	0.00627	0.012	CcSEcCtD
Phylloquinone—Erythema—Erlotinib—pancreatic cancer	0.00621	0.0119	CcSEcCtD
Phylloquinone—Sweating increased—Irinotecan—pancreatic cancer	0.00619	0.0118	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—CXCL8—pancreatic cancer	0.00606	0.0127	CbGpPWpGaD
Phylloquinone—Necrosis—Epirubicin—pancreatic cancer	0.00601	0.0115	CcSEcCtD
Phylloquinone—Phlebitis—Docetaxel—pancreatic cancer	0.0059	0.0113	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—HRAS—pancreatic cancer	0.00586	0.0123	CbGpPWpGaD
Phylloquinone—Injection site pain—Epirubicin—pancreatic cancer	0.00578	0.0111	CcSEcCtD
Phylloquinone—Swelling—Docetaxel—pancreatic cancer	0.00576	0.011	CcSEcCtD
Phylloquinone—Flushing—Sunitinib—pancreatic cancer	0.00573	0.011	CcSEcCtD
Phylloquinone—Immune system disorder—Sunitinib—pancreatic cancer	0.00557	0.0107	CcSEcCtD
Phylloquinone—Necrosis—Doxorubicin—pancreatic cancer	0.00556	0.0106	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—PCSK1—pancreatic cancer	0.00554	0.0116	CbGpPWpGaD
Phylloquinone—Sweating—Irinotecan—pancreatic cancer	0.00543	0.0104	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—PIK3CA—pancreatic cancer	0.00537	0.0113	CbGpPWpGaD
Phylloquinone—Erythema—Sunitinib—pancreatic cancer	0.00537	0.0103	CcSEcCtD
Phylloquinone—Injection site pain—Doxorubicin—pancreatic cancer	0.00535	0.0102	CcSEcCtD
Phylloquinone—Sweating—Gemcitabine—pancreatic cancer	0.00529	0.0101	CcSEcCtD
Phylloquinone—Hyperbilirubinaemia—Epirubicin—pancreatic cancer	0.00519	0.00993	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—AKT1—pancreatic cancer	0.00517	0.0108	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—PPP2R5B—pancreatic cancer	0.00507	0.0106	CbGpPWpGaD
Phylloquinone—Hyperhidrosis—Tamoxifen—pancreatic cancer	0.00495	0.00947	CcSEcCtD
Phylloquinone—Inflammation—Epirubicin—pancreatic cancer	0.00487	0.00931	CcSEcCtD
Phylloquinone—Hyperbilirubinaemia—Doxorubicin—pancreatic cancer	0.0048	0.00919	CcSEcCtD
Phylloquinone—Flushing—Irinotecan—pancreatic cancer	0.00472	0.00903	CcSEcCtD
Phylloquinone—Injection site reaction—Epirubicin—pancreatic cancer	0.00469	0.00898	CcSEcCtD
Phylloquinone—Immune system disorder—Irinotecan—pancreatic cancer	0.00459	0.00879	CcSEcCtD
Phylloquinone—Dyspnoea—Tamoxifen—pancreatic cancer	0.00456	0.00873	CcSEcCtD
Phylloquinone—Dyspnoea—Erlotinib—pancreatic cancer	0.00451	0.00864	CcSEcCtD
Phylloquinone—Inflammation—Doxorubicin—pancreatic cancer	0.0045	0.00862	CcSEcCtD
Phylloquinone—Immune system disorder—Gemcitabine—pancreatic cancer	0.00447	0.00856	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—AKT1—pancreatic cancer	0.00439	0.00919	CbGpPWpGaD
Phylloquinone—Pain—Tamoxifen—pancreatic cancer	0.00438	0.00838	CcSEcCtD
Phylloquinone—Injection site reaction—Doxorubicin—pancreatic cancer	0.00434	0.00831	CcSEcCtD
Phylloquinone—Pain—Erlotinib—pancreatic cancer	0.00433	0.00829	CcSEcCtD
Phylloquinone—Erythema—Gemcitabine—pancreatic cancer	0.00431	0.00825	CcSEcCtD
Phylloquinone—Erythema—Fluorouracil—pancreatic cancer	0.00424	0.00811	CcSEcCtD
Phylloquinone—Phlebitis—Epirubicin—pancreatic cancer	0.00398	0.00761	CcSEcCtD
Phylloquinone—Dyspnoea—Sunitinib—pancreatic cancer	0.00391	0.00748	CcSEcCtD
Phylloquinone—Hypersensitivity—Tamoxifen—pancreatic cancer	0.00377	0.00722	CcSEcCtD
Phylloquinone—Pain—Sunitinib—pancreatic cancer	0.00375	0.00717	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—TP53—pancreatic cancer	0.00372	0.00779	CbGpPWpGaD
Phylloquinone—Phlebitis—Doxorubicin—pancreatic cancer	0.00368	0.00704	CcSEcCtD
Phylloquinone—Anaphylactic shock—Irinotecan—pancreatic cancer	0.00361	0.00691	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Epirubicin—pancreatic cancer	0.00354	0.00677	CcSEcCtD
Phylloquinone—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.00352	0.00673	CcSEcCtD
Phylloquinone—Hyperhidrosis—Irinotecan—pancreatic cancer	0.00349	0.00668	CcSEcCtD
Phylloquinone—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.00346	0.00662	CcSEcCtD
Phylloquinone—Hyperhidrosis—Gemcitabine—pancreatic cancer	0.0034	0.00651	CcSEcCtD
Phylloquinone—Dizziness—Tamoxifen—pancreatic cancer	0.00338	0.00648	CcSEcCtD
Phylloquinone—Hypotension—Irinotecan—pancreatic cancer	0.00337	0.00646	CcSEcCtD
Phylloquinone—Dizziness—Erlotinib—pancreatic cancer	0.00335	0.00641	CcSEcCtD
Phylloquinone—Hypotension—Gemcitabine—pancreatic cancer	0.00329	0.00629	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Doxorubicin—pancreatic cancer	0.00328	0.00627	CcSEcCtD
Phylloquinone—Flushing—Docetaxel—pancreatic cancer	0.00326	0.00624	CcSEcCtD
Phylloquinone—Hypotension—Fluorouracil—pancreatic cancer	0.00323	0.00619	CcSEcCtD
Phylloquinone—Hypersensitivity—Sunitinib—pancreatic cancer	0.00323	0.00618	CcSEcCtD
Phylloquinone—Dyspnoea—Irinotecan—pancreatic cancer	0.00322	0.00616	CcSEcCtD
Phylloquinone—Immune system disorder—Docetaxel—pancreatic cancer	0.00317	0.00607	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—AKT1—pancreatic cancer	0.00314	0.00658	CbGpPWpGaD
Phylloquinone—Dyspnoea—Gemcitabine—pancreatic cancer	0.00314	0.006	CcSEcCtD
Phylloquinone—Pain—Irinotecan—pancreatic cancer	0.00309	0.00591	CcSEcCtD
Phylloquinone—Dyspnoea—Fluorouracil—pancreatic cancer	0.00308	0.0059	CcSEcCtD
Phylloquinone—Erythema—Docetaxel—pancreatic cancer	0.00306	0.00585	CcSEcCtD
Phylloquinone—Pain—Gemcitabine—pancreatic cancer	0.00301	0.00576	CcSEcCtD
Phylloquinone—Pain—Fluorouracil—pancreatic cancer	0.00296	0.00566	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—GCG—pancreatic cancer	0.00291	0.0061	CbGpPWpGaD
Phylloquinone—Dizziness—Sunitinib—pancreatic cancer	0.0029	0.00555	CcSEcCtD
Phylloquinone—Hypersensitivity—Irinotecan—pancreatic cancer	0.00266	0.00509	CcSEcCtD
Phylloquinone—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00255	0.00488	CcSEcCtD
Phylloquinone—Sweating—Epirubicin—pancreatic cancer	0.00253	0.00484	CcSEcCtD
Phylloquinone—Anaphylactic shock—Docetaxel—pancreatic cancer	0.0025	0.00478	CcSEcCtD
Phylloquinone—Dizziness—Irinotecan—pancreatic cancer	0.00239	0.00457	CcSEcCtD
Phylloquinone—Sweating—Doxorubicin—pancreatic cancer	0.00234	0.00448	CcSEcCtD
Phylloquinone—Hypotension—Docetaxel—pancreatic cancer	0.00233	0.00446	CcSEcCtD
Phylloquinone—Dizziness—Fluorouracil—pancreatic cancer	0.00229	0.00438	CcSEcCtD
Phylloquinone—Dyspnoea—Docetaxel—pancreatic cancer	0.00223	0.00426	CcSEcCtD
Phylloquinone—Flushing—Epirubicin—pancreatic cancer	0.0022	0.00421	CcSEcCtD
Phylloquinone—Immune system disorder—Epirubicin—pancreatic cancer	0.00214	0.0041	CcSEcCtD
Phylloquinone—Pain—Docetaxel—pancreatic cancer	0.00213	0.00409	CcSEcCtD
Phylloquinone—Erythema—Epirubicin—pancreatic cancer	0.00206	0.00395	CcSEcCtD
Phylloquinone—Flushing—Doxorubicin—pancreatic cancer	0.00204	0.00389	CcSEcCtD
Phylloquinone—Immune system disorder—Doxorubicin—pancreatic cancer	0.00198	0.00379	CcSEcCtD
Phylloquinone—Erythema—Doxorubicin—pancreatic cancer	0.00191	0.00365	CcSEcCtD
Phylloquinone—Hypersensitivity—Docetaxel—pancreatic cancer	0.00184	0.00352	CcSEcCtD
Phylloquinone—Anaphylactic shock—Epirubicin—pancreatic cancer	0.00168	0.00322	CcSEcCtD
Phylloquinone—Dizziness—Docetaxel—pancreatic cancer	0.00165	0.00316	CcSEcCtD
Phylloquinone—Hyperhidrosis—Epirubicin—pancreatic cancer	0.00163	0.00312	CcSEcCtD
Phylloquinone—Hypotension—Epirubicin—pancreatic cancer	0.00157	0.00301	CcSEcCtD
Phylloquinone—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.00156	0.00298	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—MMP2—pancreatic cancer	0.00153	0.00321	CbGpPWpGaD
Phylloquinone—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.00151	0.00288	CcSEcCtD
Phylloquinone—Dyspnoea—Epirubicin—pancreatic cancer	0.0015	0.00287	CcSEcCtD
Phylloquinone—Hypotension—Doxorubicin—pancreatic cancer	0.00146	0.00279	CcSEcCtD
Phylloquinone—Pain—Epirubicin—pancreatic cancer	0.00144	0.00276	CcSEcCtD
Phylloquinone—Dyspnoea—Doxorubicin—pancreatic cancer	0.00139	0.00266	CcSEcCtD
Phylloquinone—Pain—Doxorubicin—pancreatic cancer	0.00133	0.00255	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—CXCL8—pancreatic cancer	0.00127	0.00267	CbGpPWpGaD
Phylloquinone—Hypersensitivity—Epirubicin—pancreatic cancer	0.00124	0.00237	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—CTNNB1—pancreatic cancer	0.00117	0.00246	CbGpPWpGaD
Phylloquinone—Hypersensitivity—Doxorubicin—pancreatic cancer	0.00115	0.0022	CcSEcCtD
Phylloquinone—Dizziness—Epirubicin—pancreatic cancer	0.00111	0.00213	CcSEcCtD
Phylloquinone—Dizziness—Doxorubicin—pancreatic cancer	0.00103	0.00197	CcSEcCtD
